Compare ADMA Biologics Inc (ADMA) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Otis Worldwide Corp — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Otis Worldwide Corp trades at $72.17 (market cap $28.18B). The key difference: Otis Worldwide Corp is far larger — about 13.2× ADMA Biologics Inc's market cap, and Otis Worldwide Corp pays a 2.32% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | OTIS | |
|---|---|---|
Market Cap | $2.13B | $28.18B |
Sector | Health | Industrials |
52-Week High | $20.38 | $101.07 |
52-Week Low | $7.60 | $69.34 |
Enterprise Value | $2.20B | $35.56B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
OTIS trades at $73.43, up 0.4% today, with a bullish technical signal and strong support at $72. The company reported $14.43B in 2025 revenue, a 10.11% net income margin, and a P/E of 19.55. Recent news highlights elevator modernization projects and a 5% dividend increase to $0.44 per share. Earnings have been mixed, with a Q1 2026 miss but service segment growth.
The stock offers a 28% upside to the $94 consensus price target, supported by buybacks and dividend growth, but faces risks from high debt and margin pressure. Analyst sentiment is mixed with 38% buy ratings. Execution on service growth and cost management is critical for re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
